Episode · PRAX · Nov 9, 11:34 AM
PRAX surged +7.88% on FDA Breakthrough Therapy designation and NDA extension news. The position is holding above the opening range breakout level with the stop intact. I am holding to let the momentum run.
P0 riskansweredNov 9, 11:34 AM ET · 16 s · 1 steps · 5,733 tokens read, 349 written · qwen3.6-35b-a3b-q2 · stock-agent-v10 · level on
Why it woke
- 11:34:05 AM price P0 · 63 PRAX, which you hold, moved -3.79% since your last review at 311.91; stop 281.67.
Steps
1. Answered
15.5 s · 5733 in (0 cached) · 349 out · 41 tok/s
What came of it
PRAX surged +7.88% on FDA Breakthrough Therapy designation and NDA extension news. The position is holding above the opening range breakout level with the stop intact. I am holding to let the momentum run.
- PRAX hold · held holding
The brief it got
NOW: 2026-11-09T16:34Z WOKE FOR: PRAX (P0 risk) OBSERVATIONS - 16:34Z price, P0, salience 63: PRAX, which you hold, moved -3.79% since your last review at 311.91; stop 281.67. YOUR BOOK (the paper account: your decisions trade it; started with $10,000) cash $239.54 · equity $9931.06 (-0.69%) · today +0.28% · 11 stocks, 0 options positions - FROG: 24 shares at 103.73, now 104.73 (0.96%), stop 99.51, target 108, multi_day horizon, opened 9:46 AM ET. Thesis: FROG is the only setup in a clear long-term uptrend (price above SMA50/200, 52-week high within 2%). It broke above the 15-min opening range (102.30) on 6.9x median volume, closing at 103.11. While news is absent, the technical structure is strong: SMA20/50 at ~93.50 provide support, and the 20-day range (74-103.75) shows a steady climb. The stop at the opening range low (99.51) is 3.5% below entry, offering a tight risk profile with room to the next resistance near 108.00 (+4.7%). Invalidation: Price closes below the opening range low of 99.51. - MPC: 1 shares at 383.85, now 388.95 (1.34%), stop 312.05, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:00 AM ET. Thesis: Long-term leader: 12-month return 148.9% (skipping the last month), 25.9% above its 200-day average Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). - NBIS: 10 shares at 136.96, now 138.55 (1.09%), stop 129.47, target 145, multi_day horizon, opened 9:46 AM ET. Thesis: NBIS broke above its 15-min opening range (134.80) on 7x median volume, closing at 135.70. It has a T1 anomaly spike (+2.99% in 5 min) and upcoming earnings (Benzinga report). However, the daily trend is down (price 16% below SMA50, RSI 36.9), making this a speculative bounce play. The stop at the opening range low (129.48) is 4.5% below entry. The target of 145.00 offers a 6.8% reward. Caution is warranted due to the lack of a confirmed catalyst beyond the price shock and the downtrend. Invalidation: Price closes below the opening range low of 129.48. - PRAX: 5 shares at 304.11, now 300.1 (-1.34%), stop 281.67, target 340, multi_day horizon, opened 9:56 AM ET. Thesis: PRAX broke its 15-min opening range (281.67-289.50) on 5.4x volume, closing at 300.72. The move is backed by a T1 SEC filing (8-K) for results of operations, providing a fundamental catalyst for the surge. The price action shows strong momentum (+3.8% from OR high to close) with heavy volume support. The stop at the opening range low (281.67) is 6.3% below entry, offering a defined risk with significant upside to the next resistance level around 340. This is a high-conviction momentum play driven by a confirmed catalyst. Invalidation: Price closes below the opening range low of 281.67. - PSX: 2 shares at 248.78, now 251.73 (1.13%), stop 212.58, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:01 AM ET. Thesis: Long-term leader: 12-month return 107.2% (skipping the last month), 21.7% above its 200-day average Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). - PTC: 7 shares at 195.33, now 195.515 (0.10%), stop 190.75, target none, TREND CORE (rules-managed: its stop trails and a close below the 50-day average sells it; sell it yourself only on news that breaks the trend), multi_day horizon, opened 10:01 AM ET. Thesis: Trend core: 16.8% above a 50-day average 12.9% over the 200-day; 6-month 33% at 1.17% daily ATR (strength 28.2); 100% of its 52-week high Invalidation: The trailing stop, or a close below the 50-day average. - RVMD: 2 shares at 198.96, now 196.64 (-1.07%), stop 159.16, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:00 AM ET. Thesis: Long-term leader: 12-month return 217.0% (skipping the last month), 21.8% above its 200-day average Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). - SPY: 1 shares at 747.67, now 749.74 (0.29%), stop none, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:00 AM ET. Thesis: Long-term book: SPY at 15% of equity, held while its weekly close stays above its 200-day average: last week closed at 735.29, 0.67% vs its 200-day average 730.38. Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). - U: 2 shares at 52.97, now 51.845 (-1.93%), stop 47.67, target none, TREND CORE (rules-managed: its stop trails and a close below the 50-day average sells it; sell it yourself only on news that breaks the trend), multi_day horizon, opened 10:01 AM ET. Thesis: Trend core: 21.2% above a 50-day average 34% over the 200-day; 6-month 82.8% at 5.23% daily ATR (strength 15.84); 97% of its 52-week high Invalidation: The trailing stop, or a close below the 50-day average. - USO: 3 shares at 143.74, now 143.3 (-0.21%), stop 115.75, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:00 AM ET. Thesis: Long-term leader: 12-month return 107.8% (skipping the last month), 17.8% above its 200-day average Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). - VLO: 1 shares at 352.24, now 354.71 (0.70%), stop 300.25, target none, LONG-TERM BOOK (rules-managed: held for months until a week closes below its 200-day average; sell it yourself only on news that breaks the long-term case), multi_day horizon, opened 10:00 AM ET. Thesis: Long-term leader: 12-month return 160.8% (skipping the last month), 19.4% above its 200-day average Invalidation: A week closing below its 200-day average (a leader also: its trailing stop, or dropping out of the top at a month's refresh). LIMITS (enforced by code) - Market: the regular session. New buys: allowed. - Your envelope: 3/8 entries in 24 h, 0/3 in the last hour, 3/4 open; one action per ticker per 30 min; no re-entry for 6 h after a stop-out or 2 h after an exit. - Sizing is code's: a buy risks 1% of equity at its stop (×0.75 at conviction 6, up to ×1.25 at 10), up to 25% of equity per position ($2482.77). A closer stop means more shares; leave allocation_pct null. - Risk checks: 5/8 positions; conviction ≥ 6/10 (no intraday buys in the closing window); price ≥ $5; stop 0.4-10% below the price (default 2.5%); reward:risk ≥ 1.2; no rebuy within 15 min of a sale; $40.92 deployable cash. - Options: open premium $0 of the 25% of equity cap ($2483); at most 4% of equity per position; 0/6 positions; conviction ≥ 7; long calls and puts, call and put debit spreads; buy |delta| 0.25-0.7, 7-45 days to expiration; contracts only from an option_menu result in this episode; exits default to -60% / +150% of the position's value, and code closes positions before expiration. - Intraday stock positions are closed by code in the last minutes of the session; overnight and multi-day ones stay. Stops and targets rest at the broker as bracket or OCO orders, and once a position is up by its stop distance code trails its stop at that distance behind the price. MARKET - SPY 749.74 (+1.95%), QQQ 675.02 (+2.85%), IWM 281.01, DIA 521.36, VIXY 18.965, TLT 81.93 SUBJECT PRA… [cut: 10,491 characters in all]
Its answer as written
{
"decisions": [
{
"symbol": "PRAX",
"action": "hold",
"allocation_pct": null,
"sell_pct": null,
"stop_loss": null,
"take_profit": null,
"horizon": "multi_day",
"setup": "momentum",
"conviction": 8,
"rationale": "PRAX is up +7.88% today on strong T1/T2 catalysts: FDA Breakthrough Therapy designation for Elsunersen and an extended NDA review date for Relutrigine. The stock broke its 15-min opening range (281.67-289.50) on 5.4x volume and is currently trading at 300.10, well above the initial breakout level. The stop at 281.67 remains intact and provides a defined risk floor. The thesis (catalyst-driven momentum) is active and unbroken. No reason to exit or adjust yet.",
"evidence": [
"Price 300.10, +7.88% today",
"Breakthrough Therapy designation (T2)",
"NDA review extended (T2)",
"Volume 5.4x median",
"Stop 281.67 intact"
],
"invalidation": "Price closes below 281.67 (opening range low) or news reverses the FDA sentiment.",
"structure_id": null,
"option": null
}
],
"watches": [],
"cancel_watches": [],
"notes": [],
"reply": "PRAX surged +7.88% on FDA Breakthrough Therapy designation and NDA extension news. The position is holding above the opening range breakout level with the stop intact. I am holding to let the momentum run."
}